Cicatricial pemphigoid treated with intravenous immunoglobulin

Urcelay, M.; McQueen, A.; Douglas, W.S.

doi:10.1111/j.1365-2133.1997.tb03770.x

Cited by 31 publications

(18 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Overall, treatment of MMP is difficult, despite the use of corticosteroids combined with other immunosuppressants. At least 70 patients with severe widespread MMP resistant to conventional therapies were reported to be successfully treated with IVIG as adjuvant therapy [28, [50][51][52][53][54][55][56][57][58]. Most case reports have shown IVIG given at 2 g/kg/cycle initially every 2-3 weeks is a therapeutic option.…”

Section: Subepidermal Blistering Diseasesmentioning

confidence: 99%

High-Dose Intravenous Immunoglobulin (IVIG) Therapy in Autoimmune Skin Blistering Diseases

Ishii

Hashimoto

Zillikens

et al. 2009

Clinic Rev Allerg Immunol

View full text Add to dashboard Cite

Treatment of autoimmune bullous skin diseases can often be challenging and primarily consists of systemic corticosteroids and a variety of immunosuppressants. Current treatment strategies are effective in most cases but hampered by the side effects of long-term immunosuppressive treatment. Intravenous immunoglobulin (IVIG) is one potential promising therapy for patients with autoimmune bullous skin diseases, and evidence of its effectiveness and safety is increasing. A number of autoimmune bullous skin diseases have been identified in which IVIG treatment may be beneficial. However, experience with IVIG in patients with autoimmune skin blistering disease is limited, where it is recommended for patients not responding to conventional therapy. The mode of action of IVIG in autoimmune diseases, including bullous diseases is far from being completely understood. We here summarize the clinical evidence supporting the notion, that IVIG is a promising therapeutic agent for the treatment of patients with autoimmune bullous skin disease. In addition, we review the proposed modes of action. In the future, randomized controlled trials are necessary to better determine the efficacy and adverse effects of IVIG in the treatment of autoimmune bullous skin diseases. In addition, insights into IVIG's mode of action might enable us to develop novel therapeutics to overcome the current shortage of IVIG.

show abstract

Section: Subepidermal Blistering Diseasesmentioning

confidence: 99%

High-Dose Intravenous Immunoglobulin (IVIG) Therapy in Autoimmune Skin Blistering Diseases

Ishii

Hashimoto

Zillikens

et al. 2009

Clinic Rev Allerg Immunol

View full text Add to dashboard Cite

show abstract

“…In 1997, Urcelay et al . [32] reported two cases who had successful treatment with IVIg therapy. In the first case, a 50-year-old woman was diagnosed at MMP in 1992; betamethasone and cyclosporine did not control the disease completely.…”

Section: Methodsmentioning

confidence: 99%

The role of intravenous immunoglobulin in treatment of mucous membrane pemphigoid: A review of literature

Tavakolpour

2016

J Res Med Sci

View full text Add to dashboard Cite

Background:Mucous membrane pemphigoid (MMP) is considered an autoimmune blistering disease that predominantly affects mucous membranes. Various treatments are available for controlling the diseases, but not all of them may respond.Materials and Methods:PubMed and Google Scholar were searched for all the associated studies until 2015, using the keywords such as “cicatricial pemphigoid” or “ocular pemphigoid” or “mucous membrane pemphigoid” or “MMP” and “intravenous immunoglobulin” or “IVIg” to find all the relevant studies. The last search update was for September 2, 2015. Among the searched items, only English studies were included in the review.Results:After excluding nonrelevant studies, 13 studies with a total number of seventy patients with MMP who were under treatment with IVIg were analyzed. The 65 patients responded completely, one did not respond, two had partially responded, and the remaining two patients stopped IVIg therapy, which resulted in ocular cicatricial pemphigoid progression. Majority of the studies reported mild adverse effects while two of them did not report any unwanted side effect. The most common side effect was headache, followed by nausea. Most of the patients who had a cessation of IVIg therapy before achieving clinical remission experienced the disease progression.Conclusion:Overall, it can be concluded that IVIg therapy was very helpful in treatment of MMP patients who did not respond to conventional therapy or stopped using them for various side effects. Adverse effects associated with IVIg therapy were considerably lower than conventional therapy that can lead toward treatment with this agent in patients who suffer from severe side effects.

show abstract

“…These include blockage of Fc receptors, alteration of cytokine production, cytokine antagonism, inhibition of complement-mediated damage, and neutralization of circulating autoantibodies (Andersson et al 1996; Jolles et al 1998). The successful use of IVIG in the treatment of MMP was initially reported in two patients (Urcelay et al 1997). Foster and Ahmed (1999) later reported on their experience in ten patients.…”

Section: Severe Diseasementioning

confidence: 99%

Treatment strategies in mucous membrane pemphigoid

Neff¹

2008

TCRM

View full text Add to dashboard Cite

Mucous membrane pemphigoid (MMP) is an autoimmune blistering disorder that is characterized by subepithelial bullae. Various basement membrane zone components have been identifi ed as targets of autoantibodies in MMP. Considerable variability exists in the clinical presentation of MMP. Mucous membranes that may be involved include the oral cavity, conjunctiva, nasopharynx, larynx, esophagus, genitourinary tract, and anus. A multidisciplinary approach is essential in the management of MMP. Early recognition of this disorder and treatment may decrease disease-related complications. The choice of agents for treatment of MMP is based upon the sites of involvement, clinical severity, and disease progression. For more severe disease, or with rapid progression, systemic corticosteroids are the agents of choice for initial treatment, combined with steroid-sparing agents for long-term maintenance. Due to the rarity of this disease, large controlled studies comparing the effi cacy of various agents are lacking.

show abstract

Cicatricial pemphigoid treated with intravenous immunoglobulin

Cited by 31 publications

References 10 publications

High-Dose Intravenous Immunoglobulin (IVIG) Therapy in Autoimmune Skin Blistering Diseases

High-Dose Intravenous Immunoglobulin (IVIG) Therapy in Autoimmune Skin Blistering Diseases

The role of intravenous immunoglobulin in treatment of mucous membrane pemphigoid: A review of literature

Treatment strategies in mucous membrane pemphigoid

Contact Info

Product

Resources

About